248 related articles for article (PubMed ID: 28346042)
1. Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.
Tian X; Han Y; Yu L; Luo B; Hu Z; Li X; Yang Z; Wang X; Huang W; Wang H; Zhang Q; Ma D
Cancer Biol Ther; 2017 Apr; 18(4):245-251. PubMed ID: 28346042
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer.
Zhou Q; Mei YD; Yang HJ; Tao YL
Future Oncol; 2021 May; 17(15):1889-1906. PubMed ID: 33728938
[No Abstract] [Full Text] [Related]
3. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of cancer stem cell markers, SALL4/ALDH1A1, is associated with tumor aggressiveness and poor survival in patients with serous ovarian carcinoma.
Sharbatoghli M; Shamshiripour P; Fattahi F; Kalantari E; Habibi Shams Z; Panahi M; Totonchi M; Asadi-Lari Z; Madjd Z; Saeednejad Zanjani L
J Ovarian Res; 2022 Jan; 15(1):17. PubMed ID: 35090523
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
6. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
Zhou X; Teng L; Wang M
Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer.
Miree O; Srivastava SK; Khan MA; Sameeta F; Acharya S; Ndetan H; Singh KP; Hertweck KL; Dasgupta S; da Silva LM; Rocconi RP; Carter JE; Singh S; Singh AP
Sci Rep; 2021 Jun; 11(1):12901. PubMed ID: 34145334
[TBL] [Abstract][Full Text] [Related]
8. Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer.
Xin B; Ji KQ; Liu YS; Zhao XD
J Ovarian Res; 2019 Aug; 12(1):75. PubMed ID: 31399054
[TBL] [Abstract][Full Text] [Related]
9. Prognostic roles of Notch receptor mRNA expression in human ovarian cancer.
Chen C; Wang X; Huang S; Wang L; Han L; Yu S
Oncotarget; 2017 May; 8(20):32731-32740. PubMed ID: 28415574
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of the lysyl oxidase family in ovarian cancer.
Ye M; Zhou J; Gao Y; Pan S; Zhu X
J Clin Lab Anal; 2020 Dec; 34(12):e23538. PubMed ID: 33058284
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer.
Zheng R; Chen W; Xia W; Zheng J; Zhou Q
Biomed Res Int; 2020; 2020():7658782. PubMed ID: 33282953
[TBL] [Abstract][Full Text] [Related]
12. REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.
Jia W; Chang B; Sun L; Zhu H; Pang L; Tao L; Zou H; Du J; Dong Y; Qi Y; Jiang J; Liang W; Li F; Zhao X
Int J Clin Exp Pathol; 2014; 7(9):5940-9. PubMed ID: 25337238
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
15. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
16. Prognostic values of S100 family mRNA expression in ovarian cancer.
Ma N; Zhu L; Yang L; Cui Y; Zhan Y
Cancer Biomark; 2019; 25(1):67-78. PubMed ID: 31033462
[TBL] [Abstract][Full Text] [Related]
17. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
19. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract][Full Text] [Related]
20. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
